D. Boral Capital Reiterates Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have a $21.00 price target on the stock. D. Boral Capital’s price target would indicate a potential upside of 415.97% from the company’s current price.

Several other analysts have also recently issued reports on TRVI. B. Riley reaffirmed a “buy” rating and set a $6.00 target price on shares of Trevi Therapeutics in a research report on Monday, October 7th. HC Wainwright raised their price objective on Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a research report on Thursday, December 12th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research note on Thursday, December 12th. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Trevi Therapeutics presently has an average rating of “Buy” and an average price target of $9.31.

Trevi Therapeutics Price Performance

TRVI stock opened at $4.07 on Wednesday. Trevi Therapeutics has a 1-year low of $1.27 and a 1-year high of $4.68. The business has a 50-day moving average price of $3.35 and a 200 day moving average price of $3.12. The company has a market capitalization of $312.84 million, a P/E ratio of -9.25 and a beta of 0.87.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same quarter last year, the company posted ($0.08) EPS. On average, analysts anticipate that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Trevi Therapeutics

Large investors have recently modified their holdings of the business. Ally Bridge Group NY LLC purchased a new position in shares of Trevi Therapeutics in the 2nd quarter valued at approximately $4,395,000. Logos Global Management LP raised its holdings in shares of Trevi Therapeutics by 27.3% in the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock worth $8,344,000 after buying an additional 600,000 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Trevi Therapeutics during the third quarter worth $409,000. Geode Capital Management LLC grew its holdings in shares of Trevi Therapeutics by 10.2% during the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock valued at $4,223,000 after buying an additional 117,418 shares during the last quarter. Finally, Fred Alger Management LLC purchased a new stake in shares of Trevi Therapeutics during the third quarter valued at $256,000. Hedge funds and other institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.